


Reflect - text mining in Semantic Web

a practical approach to web semantics



The Novo Nordisk Foundation
Center for Protein Research



DET SUNDHEDSVIDENSKABELIGE FAKULTET
KØBENHAVNS UNIVERSITET

Mechanism of action

[\[edit\]](#)

Unlike the similarly-named [tacrolimus](#), sirolimus is not a [calcineurin inhibitor](#). However, it has a similar suppressive effect on the immune system. Sirolimus inhibits the response to [interleukin-2](#) (IL-2) and thereby blocks activation of [T-](#) and [B-cells](#). In contrast, tacrolimus inhibits the production of IL-2.

The mode of action of sirolimus is to bind the [cytosolic](#) protein *FK-binding protein 12* (FKBP12) in a manner similar to tacrolimus. However, unlike the tacrolimus-FKBP12 complex which inhibits [calcineurin](#) (PP2B), the sirolimus-FKBP12 complex inhibits the [mammalian target of rapamycin](#) (mTOR) pathway by directly binding the mTOR Complex1 (mTORC1). mTOR is also called FRAP (FKBP-rapamycin associated protein) or RAFT (rapamycin and FKBP target). FRAP and RAFT are actually more accurate names since they reflect the fact that rapamycin must bind FKBP12 first, and only the FKBP12-rapamycin complex can bind FRAP/RAFT/mTOR.

Mechanism of action

[\[edit\]](#)

Unlike the similarly-named **tacrolimus**, **sirolimus** is not a **calcineurin inhibitor**. However, it has a similar suppressive effect on the immune system. **Sirolimus** inhibits the response to **interleukin-2** (IL-2) and thereby blocks activation of **T-** and **B-cells**. In contrast, **tacrolimus** inhibits the production of **IL-2**.

The mode of action of **sirolimus** is to bind the **cytosolic** protein *FK-binding protein 12* (**FKBP12**) in a manner similar to **tacrolimus**. However, unlike the **tacrolimus**-**FKBP12** complex which inhibits **calcineurin** (PP2B), the **sirolimus**-**FKBP12** complex inhibits the **mammalian target of rapamycin** (**mTOR**) pathway by directly binding the **mTOR** Complex1 (mTORC1). **mTOR** is also called **FRAP** (FKBP-rapamycin associated protein) or RAFT (**rapamycin** and **FKBP** target). **FRAP** and RAFT are actually more accurate names since they reflect the fact that **rapamycin** must bind **FKBP12** first, and only the **FKBP12**-**rapamycin** complex can bind **FRAP/RAFT/mTOR**.

Current Status in publication process

- not widely used
- won't change soon because:
 - authors tend to do as much as needed
 - more work for publishers

Reflect approach

- Easy
- Fast
- Versatile

Mechanism of action

[\[edit\]](#)

Unlike the similarly-named **tacrolimus**, **sirolimus** is not a **calcineurin inhibitor**. However, it has a similar suppressive effect on the immune system. **Sirolimus** inhibits the response to **interleukin-2** (IL-2) and thereby blocks activation of **T-** and **B-cells**. In contrast, **tacrolimus** inhibits the production of **IL-2**.

The mode of action of **sirolimus** is to bind the **cytosolic** protein *FK-binding protein 12* (**FKBP12**) in a manner similar to **tacrolimus**. However, unlike the **tacrolimus**-**FKBP12** complex which inhibits **calcineurin** (PP2B), the **sirolimus**-**FKBP12** complex inhibits the **mammalian target of rapamycin** (**mTOR**) pathway by directly binding the **mTOR** Complex1 (mTORC1). **mTOR** is also called **FRAP** (FKBP-rapamycin associated protein) or **RAFT** (**rapamycin** and **FKBP** target). **FRAP** and **RAFT** are actually more accurate names since they reflect the fact that **rapamycin** must bind **FKBP12** first, and only the **FKBP12**-**rapamycin** complex can bind **FRAP/RAFT/mTOR**.


Chemicals

Mechanism of action

[\[edit\]](#)

Unlike the similarly-named **tacrolimus**, **sirolimus** **Sirolimus** inhibits the response to **interleukin-2** (IL-2) production of **IL-2**.

The mode of action of **sirolimus** is to bind the **cyt** unlike the **tacrolimus**-**FKBP12** complex which inhibits the **rapamycin** (mTOR) pathway by directly binding to the **protein** or **RAFT** (**rapamycin** and **FKBP** target). **Sirolimus** must bind **FKBP12** first, and only the **FKBP12**-**ra**



ssive effect on the immune system.

st, **tacrolimus** inhibits the

imilar to **tacrolimus**. However,

bits the **mammalian target of**

(FKBP-rapamycin associated

y reflect the fact that **rapamycin**

Proteins

Mechanism of action

[edit]

Unlike the similarly-named **tacrolimus**, **sirolimus** is not a **calcineurin inhibitor**. However, it has a similar suppressive effect on the immune system. **Sirolimus** inhibits the response to **interleukin-2** (IL-2) and thereby blocks activation of **T-** and **B-cells**. In contrast, **tacrolimus** inhibits the production of **IL-2**.

The mode of action of **sirolimus** is to bind the **cytosolic** protein **FK-binding protein 12** (FKBP12) in a manner similar to **tacrolimus**. However, unlike the **tacrolimus**-FKBP12 complex which inhibits **calcineurin** (PP2B), the **sirolimus**-FKBP12 complex inhibits the **mammalian target of rapamycin** (mTOR) pathway by directly binding the mTOR protein) or RAFT (**rapamycin** and FKBP target). **FRAP** and must bind **FKBP12** first, and only the **FKBP12-rapamycin** c

rapamycin associated
e fact that **rapamycin**

mTOR

Protein

FRAP1 (ENSP00000354587) ▼ H. sapiens Edit

mTOR; mammalian target of rapamycin; FRAP; RAFT1; FRAPP; rapam

FRAP_HUMAN Literature Sequence Structure Locus Domains

MLGTGPA A A A T T A A T T S S N V S V L Q Q F A S G L K S R N E E T R A K A A K E L Q

FKBP12-rapamycin complex-associated protein (FK506-binding protein 12- rapamycin complex-associated protein 1) (Rapamycin


Add Name

Mechanism of action

[\[edit\]](#)

Unlike the similarly-named **tacrolimus**, **sirolimus** is not a **calcineurin inhibitor**. However, it has a similar suppressive effect on the immune system. **Sirolimus** inhibits the response to **interleukin-2 (IL-2)** and thereby blocks activation of **T-** and **B-cells**. In contrast, **tacrolimus** inhibits the production of **IL-2**.

The mode of action of **sirolimus** is to bind the **cytosolic** protein **FK-binding protein 12 (FKBP12)** in a manner similar to **tacrolimus**. However, unlike the **tacrolimus-FKBP12** complex which inhibits **calcineurin (PP2B)**, the **sirolimus-FKBP12** complex inhibits the **mammalian target of rapamycin (mTOR)** pathway by directly binding the **mTOR** Complex1 (mTORC1). **mTOR** is also called **FRAP** (FKBP-rapamycin associated protein) or **RAFT** (**rapamycin and FKBP target**). **FRAP** and **RAFT** are actually more accurate names since they reflect the fact that **rapamycin** must bind **FKBP12**. The **sirolimus-FKBP12** complex can bind **FRAP/RAFT/mTOR**.

- Copy
- Select All
- Search Google for "RAFT"
- View Selection Source
-  Inspect Element
- Download Selection with iGetter...
- Download All with iGetter...
- Reflect
- Add 'RAFT' to Reflect
- Remove Word from Page Interactions

Blacklist Name


Mechanism of action

[edit]

Unlike the similarly-named **tacrolimus**, **sirolimus** is not a **calcineurin inhibitor**. However, it has a similar suppressive effect on the immune system. **Sirolimus** inhibits the response to **interleukin-2** (IL-2) and thereby blocks activation of **T-** and **B-cells**. In contrast, **tacrolimus** inhibits the production of **IL-2**.

The mode of action of **sirolimus** is to bind the **cytosolic** protein **FK-binding protein 12** (FKBP12) in a manner similar to **tacrolimus**. However, unlike the **tacrolimus**-FKBP12 complex which inhibits **calcineurin** (PP2B), the **sirolimus**-FKBP12 complex inhibits the **mammalian target of rapamycin** (mTOR) pathway. **mTOR** is also called **FRAP** (FKBP-rapamycin associated protein) or **RAFT** (rapamycin associated factor). **FRAP** and **RAFT** are actually more accurate names since they reflect the fact that **rapamycin** must bind **FKBP12** first, and then the complex can bind **FRAP/RAFT/mTOR**.

- Back
- Forward
- Reload
- Stop
- Bookmark This Page
- Save Page As...
- Send Link...
- View Background Image
- Select All
- View Page Source
- View Page Info
- Reflect
- Add Word to Reflect
- Remove 'FKBP12' from Page Interactions



Reflect – Highlighting Proteins, and Small Molecule Names.

http://reflect.ws/ Reflect Google

Most Visited Getting Started Latest Headlines

Reflect – Highlighting Proteins, an... +

http://en.wikipedia.org/wiki/Sirolimus Reflect Download About

Try Beta Log in / create account

article discussion edit this page history

Sirolimus

From Wikipedia, the free encyclopedia


Sirolimus (INN/USAN), also known as **rapamycin**, is an immunosuppressant drug used to prevent rejection in organ transplantation; it is especially useful in kidney transplants. A macrolide, sirolimus was first discovered as a product of the bacterium *Streptomyces hygroscopicus* in a soil sample from Easter Island^[1] — an island also known as "Rapa Nui", hence the name.^[2] It is marketed under the trade name **Rapamune** by Wyeth.

Sirolimus was originally developed as an antifungal agent. However, this was abandoned when it was discovered that it had potent immunosuppressive and antiproliferative properties. It has since been shown to prolong the life of mice and might also be useful in the treatment of certain cancers.

Contents [hide]

- Mechanism of action
- Use in transplant
- Lifespan extension in mice
- Anti-proliferative effects
- Tuberous sclerosis complex
- Cancer
- Potential treatment for autism


Sirolimus




Done

Plug-In

- Firefox



- Internet Explorer



- Bookmarklet



Technical details

- Tagging Server
 - 7.4 million Chemicals (24.2 million synonyms)
 - 2.6 million Proteins (20.6 million synonyms)
 - 32GB of memory
- Queuing System

API Services

- provide tagged document
 - GetHTML
- URL to document on the Reflect server
 - GetURI
- XML of found names
 - GetEntities

API protocol

- REST
- SOAP

API Input

- document

AND/OR

- document identifier
(URI, DOI)

GetHTML Examples

<http://reflect.cbs.dtu.dk/REST/GetHTML?document=<html>....</html>>

<http://reflect.cbs.dtu.dk/REST/GetHTML?URI=http://en.wikipedia.org/wiki/Sirolimus>

<http://reflect.cbs.dtu.dk/REST/GetHTML?DOI=10.1006/jmbi.1998.2345>

GetHTML Examples

- Entity Type
 - Taxonomy ID
 - -1 => Chemicals
- Autodetect Entities
- Autodetect DOI

GetHTML Examples


<http://reflect.cbs.dtu.dk/REST/GetHTML?document=<html>....</html>>

<http://reflect.cbs.dtu.dk/REST/GetHTML?URI=http://en.wikipedia.org/wiki/Sirolimus>

<http://reflect.cbs.dtu.dk/REST/GetHTML?DOI=10.1006/jmbi.1998.2345>

http://reflect.cbs.dtu.dk/REST/GetHTML?document=<html>...</html>&entity_types=-1 9606 10090&uri=http://en.wikipedia.org/wiki/Sirolimus

GetHTML Example



WIKIPEDIA
The Free Encyclopedia

navigation

- Main page
- Contents
- Featured content
- Current events
- Random article

search

Go Search

interaction

- About Wikipedia
- Community portal
- Recent changes
- Contact Wikipedia
- Donate to Wikipedia
- Help

toolbox

- What links here
- Related changes
- Upload file
- Special pages
- Printable version
- Permanent link
- Cite this page

languages

- Deutsch
- Français
- 한국어
- Italiano
- Nederlands
- 日本語
- Polski

[article](#) [discussion](#) [edit this page](#) [history](#)

Sirolimus

From Wikipedia, the free encyclopedia

Sirolimus (INN/USAN), also known as **rapamycin**, is an immunosuppressant drug used to prevent rejection in organ transplantation; it is especially useful in kidney transplants. A macrolide, sirolimus was first discovered as a product of the bacterium *Streptomyces hygroscopicus* in a soil sample from Easter Island^[1] — an island also known as "Rapa Nui", hence the name.^[2] It is marketed under the trade name **Rapamune** by Wyeth.

Sirolimus was originally developed as an antifungal agent. However, this was abandoned when it was discovered that it had potent immunosuppressive and antiproliferative properties. It has since been shown to prolong the life of mice and might also be useful in the treatment of certain cancers.

Contents [hide]

- 1 Mechanism of action
- 2 Use in transplant
- 3 Lifespan extension in mice
- 4 Anti-proliferative effects
- 5 Tuberous sclerosis complex
- 6 Cancer
- 7 Potential treatment for autism
- 8 Biosynthesis
- 9 Costs
- 10 References
- 11 External links

Mechanism of action



Unlike the similarly-named tacrolimus, sirolimus is not a calcineurin inhibitor. However, it has a similar suppressive effect on the immune system. Sirolimus inhibits the response to interleukin-2 (IL-2) and thereby blocks activation of T- and B-cells. In contrast, tacrolimus inhibits the production of IL-2.

The mode of action of sirolimus is to bind the cytosolic protein *FK-binding protein 12* (FKBP12) in a manner similar to tacrolimus. However, unlike the tacrolimus-FKBP12 complex which inhibits calcineurin (PP2B), the sirolimus-FKBP12 complex inhibits the mammalian target of rapamycin (mTOR) pathway by directly binding the mTOR Complex1 (mTORC1). mTOR is also called FRAP (FKBP-rapamycin associated protein) or RAFT (rapamycin and FKBP target). FRAP and RAFT are actually more accurate names since they reflect the fact that rapamycin must bind FKBP12 first, and only the FKBP12-rapamycin complex can bind FRAP/RAFT/mTOR.

Use in transplant

Try Beta [Log in/create account](#)

Sirolimus



Systematic (IUPAC) name

(3*S*,6*R*,7*E*,9*R*,10*R*,12*R*,14*S*,15*E*,17*E*,19*E*,21*S*,23*S*,26*R*,27*R*,34*aS*)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-[(1*R*)-2-[(1*S*,3*R*,4*R*)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3*H*-pyrido[2,1-*c*][1,4]-oxaazacyclohentrtriacontine-1,5,11,26,29(4*H*,6*H*,31*H*)-pentone

GetEntities Example

```
<item>
  <name>FRAP</name>
  <count>2</count>
  <entities>
    <entity>
      <type>10090</type>
      <identifier>ENSMUSP00000099510</identifier>
    </entity>
    <entity>
      <type>10090</type>
      <identifier>ENSMUSP00000032971</identifier>
    </entity>
    <entity>
      <type>9606</type>
      <identifier>ENSP00000350934</identifier>
    </entity>
    <entity>
      <type>9606</type>
      <identifier>ENSP00000354587</identifier>
    </entity>
  </entities>
</item>
```

SOAP

- CSS Styles

SOAP Request Example

```
<GetHTML>
  <document_id id_type="URI">http://en.wikipedia.org/wiki/
Sirolimus</document_id>
  <entity_types auto_detect="0">
    <entity_type>9606</entity_type>
    <entity_type>-1</entity_type>
  </entity_types>
  <styles>
    <style entity_type="0">background-color: #99DDDD;</style>
    <style entity_type="-1">background-color: #FFCC99;</style>
  </styles>
</GetHTML>
```


Cell – Reduced IGF-1 Signaling Delays Age-Associated Proteotoxicity in Mice

http://www.cell.com/fulltext/S0092-8674(09)01426-3

Most Visited Getting Started Latest Headlines New Bookmark

Cell – Reduced IGF-1 Signaling De... +

Cell

Cell Cell Cell Cell

Login Register Subscribe Alerts

Search by: ☒ Full Text ☐ Authors Search

or go to Advanced Search

Home Current Issue Archive For Authors Journal Information Conferences Jobs Change Journal Cell Press

Cell Lab Links
PRESS BOSTON AREA SYMPOSIA

Neurogenetics
March 4, 2010 – Broad Institute, Cambridge, MA
REGISTRATION IS FREE! Learn More>>

Copyright © 2009 Elsevier Inc.. All rights reserved.
Cell, Volume 139, Issue 6, 1157-1169, 11 December 2009
doi:10.1016/j.cell.2009.11.014

Previous Article Table of Contents Next Article

Article

Reduced IGF-1 Signaling Delays Age-Associated Proteotoxicity in Mice

Ehud Cohen^{1,7}, Johan F. Paulsson², Pablo Blinder³, Tal Burstyn-Cohen⁴, Deguo Du², Gabriela Estepa¹, Anthony Adame⁵, Hang M. Pham⁵, Martin Holzenberger⁶, Jeffery W. Kelly², Eliezer Masliah⁵ and Andrew Dillin^{1,2,5}

¹ Howard Hughes Medical Institute, Glenn Center for Aging Research, Molecular and Cell Biology Laboratory, The Salk Institute for Biological Studies, 10010 North Torrey Pines Road, La Jolla, CA 92037, USA
² Department of Chemistry and Molecular and Experimental Medicine and The Skaggs Institute of Chemical Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
³ Department of Physics, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA
⁴ Molecular Neurobiology Laboratory, The Salk Institute for Biological Studies, 10010 North Torrey Pines Road, La Jolla, CA 92037, USA
⁵ Department of Neurosciences, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA
⁶ INSERM and Université Pierre-et-Marie-Curie, UMR5 938, Hôpital Saint-Antoine, 75571 Paris 12, France

[✉] Corresponding author

⁷ Present address: Department of Biochemistry and Molecular Biology, the Institute for Medical Research Israel-Canada, The Hebrew University Medical School, Ein Kerem, Jerusalem 91120, Israel

Reflect
Reflect highlights proteins and small molecules and provides links to information-rich summaries.
Cell is using Reflect on a trial basis. Tell us what you think.
Click here to turn off Reflect.
Add/View Comments (0)

Article Outline X

Summary
Introduction
Results
Discussion
Experimental Procedures
Acknowledgments
Supplemental Data
References
Publication Information

Article Information
[PDF \(1935 kb\)](#)
[Full Text with Large Figures](#)
[Supplemental Data](#)
[Export Citation](#)
[Request permission](#)

PubMed
[Articles by Ehud Cohen](#)
[Articles by Andrew Dillin](#)

Related Articles
[Role of IGF Signaling in Olfactory Sensory Map Formation and...](#)
[IGF signaling defects as causes of growth failure and IUGR](#)
[Sex and Death: What is the Connection?](#)
[...more](#)

Get Bookmark
[Add Bookmark](#)

Related Resources from Featured Advertisers
Learn more about the various signal transduction pathways
[Cell Signaling Technology, Inc](#)

Done

Acknowledgements

EMBL

Seán O'Donoghue
Evangelos Pafilis
Sven Haag
Venkata P. Satagopam
Michael Kuhn
Reinhard Schneider

CPR

Lars Juhl Jensen
Damian Szklarczyk
Sune Pleischer-Frankild